INTRODUCTION AND OBJECTIVES: Since 2014 version, the National Comprehensive Cancer Network (NCCN) guidelines for prostate cancer (PCa) have further subdivided high-risk group to separate patients thought to have the worst prognosis into the very high-risk (VHR) category. The revised criteria for VHR include clinical stage ! T3b or primary Gleason 5 or ! 5 biopsy cores with Gleason 8-10.
High-dose-rate brachytherapy (HDRBT) allows dose escalation while minimizing acute or late toxicity, and has been widely applied especially in high risk or locally advanced PCa. However, there remains little clear evidence of benefit of this treatment modality in VHR subpopulation.
The purpose of this study was to report the outcomes of HDRBT and hypofractionated external beam radiotherapy (EBRT) combined with long-term androgen deprivation therapy (ADT) for VHR PCa.
METHODS: Between June 2009 and September 2015, all patients who had undergone HDRBT for nonmetastatic PCa at our institution were retrospectively identified. Of these, 66 patients meeting NCCN criteria for VHR disease were included in this study. HDRBT with 2 fractions of 9 Gy was administered after completion of EBRT with 13 fractions of 3 Gy each. All patients initially underwent ! 6 months of neoadjuvant ADT, and adjuvant ADT was continued for 36 months after HDRBT. Biochemical failure (BCF) was assessed using the Phoenix definition.
RESULTS: The median (interquartile range) follow-up was 53 (41-70) months from the start of radiotherapy. The 5-year BCF-free, metastasis-free, disease-specific, and overall survival rates were 88.7%, 89.2%, 98.5%, and 97.0%, respectively. The independent contributions of each component of the VHR criteria were assessed in multivariable models. Primary Gleason 5 was associated with increased risks of BCF (HR [ 13.77; 95% CI, 1.61-118.05, P [ 0.017) and metastasis (HR [ 5.51; 95% CI, 1.01-30.08, P [ 0.049) whereas clinical stage ! T3b or ! 5 biopsy cores with Gleason 8-10 had no significant impact on the two outcomes.
Grade 3 genitourinary toxicities were observed in 2 (3.0%) patients (hematuria and urethral stricture), all of which were successfully controlled by endoscopic interventions. Neither acute nor late ! Grade 3 gastrointestinal toxicity was seen.
CONCLUSIONS: Although a longer follow-up is needed to confirm the durability of these findings, the present study indicates that this multimodal approach provides potentially excellent cancer control and acceptable associated morbidity for VHR PCa. Patients with primary Gleason 5 were at a higher risk of poor outcome, indicating a need for more aggressive approaches in these patients.
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MP72-20 IMPACT OF TADALAFIL ON ADVERSE EVENTS AFTER LOW DOSE RATE BRACHYTHERAPY FOR PROSTATE CANCER-A MULTI CENTER RANDOMIZED OPEN LABEL TRIAL
Tomohiko Oguchi*, Nagano, Japan; Tomonori Minagawa, Ayumu Fukasawa, Matsumoto, Japan; Kazuyoshi Iijima, Nagano, Japan; Keiichiro Koiwai, Matsumoto, Japan; Iwao Hashida, Nagano, Japan; Teruyuki Ogawa, Matsumoto, Japan; Haruaki Kato, Nagano, Japan; Osamu Ishizuka, Matsumoto, Japan INTRODUCTION AND OBJECTIVES: Lower urinary tract symptoms (LUTS) is a common adverse event in the acute phase after low dose rate brachytherapy (LDR) for prostate cancer. In addition, erectile dysfunction (ED) might be also problematic in the chronic phase after LDR. Alpha blockers have positive impact on LUTS after LDR. Nowadays, usefulness of tadalafil (TAD), a phosphodiesterase-5 inhibitor, was established as a treatment for male LUTS and ED. Although TAD may be theoretically useful for management of LUTS and ED after LDR, usefulness of TAD after LDR has not been reported yet. We herein investigated the efficacy of TAD to attenuate adverse events after LDR comparing tamuslosin (TAM), an alpha blocker.
METHODS: This study was a multicenter randomized openlabel trial, and was conducted at 2 hospitals in Japan. Inclusion criteria of this study is the prostate cancer patients, who were 80 years or less, T2 or less, prostate specific antigen (PSA) 10 ng/mL or less, Gleason score 3þ4 or less. They were randomly divided into 2 groups, the TAM group (0.2mg/day) and the TAD group (5mg/day). TAM and TAD were administrated from the day following LDR. PSA, international prostate symptom score (IPSS), quality-of-life (QoL) score, overactive bladder symptom score (OABSS), international index of erectile function (IIEF5), were evaluated before and 1, 3, 6, 9, 12 months after LDR. Uroflowmetry and residual urine volume were also evaluated.
RESULTS: A total of 107 patients were enrolled in this study. Finally, 96 patients were analyzed. There was no significant difference in the patient background among the groups. The summarized results were shown in Table. Improvement of IPSS in TAM group is better than TAD group, and IIEF5 in TAD group is better than TAM group 9 months after LDR. However, general course of LUTS and ED in TAD group is almost similar to TAM group during 1 year follow up. And, there are no statistical differences of the objective findings among the groups.
CONCLUSIONS: TAD can be a treatment option for management of LUTS and ED after LDR comparable to TAM. RPLNDs have been performed in 434 patients. The database of consecutive patients was queried to identify 171 patients with PC-RPLND after 1st line chemotherapy for a non-seminoma with or without bilateral template resection. Re-Dos, late relapse, salvage patients and thoracoabdominal approaches were excluded. Indication for a template resection was a unilateral residual mass mainly less than 5 cm as published (Heidenreich et al. 2009 ). Descriptive statistics were used to report preoperative features, post-operative outcomes and patterns of recurrence. Kaplan-Meier analyses were used to describe recurrence-and cancer specific mortality-free survival rates.
RESULTS: 90 and 81 patients underwent unilateral and bilateral resection, respectively. Median size of residual mass was 7 cm for bilateral and 4 cm for unilateral template resection. Clinical stage II and III were present in 31% and 69% of patients, respectively. Median follow-up was 14.5 months (IQR 3.3 e 37.6). Recurrences were observed in 5 and 18 patients for the unilateral and bilateral approach, respectively. Only five recurrences occurred in the retroperitoneum, 3 in-field and 1 outside-field recurrence after a bilateral approach, and only one outside field in a template approach. The 1-and 2-year recurrence-free survival rates were 91% and 91%, 77% and 72% for patients treated with unilateral template and bilateral resection, respectively (p<0.0008). Median time to recurrence was 9.5 and 9 months in template and bilateral PC-RPLND group, respectively.
As expected, adjunctive procedures were performed in 56 patients (33%) and were significantly more frequent in bilateral PC-RPLND group (44% vs. 22%, p<0.002). High-grade complication rate (Clavien-Dindo ! III) was 3% and 9% in unilateral template and bilateral PC-RPLND group, respectively (p[0.2). In 87% and 44% nervesparing was achieved in unilateral and bilateral approaches, respectively. In patients with complete follow-up data, the preservation rate of antegrade ejaculation was significantly higher in the unilateral group.
CONCLUSIONS: Unilateral template PC-RPLND in the 1st line setting is oncologically safe when the residual mass is < 5 cm. Nervesparing and preservation of antegrade ejaculation with a unilateral resection is significantly better.
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A SELECTIVE LYSINE-SPECIFIC DEMETHYLASE 1 INHIBITOR SUPPRESSES TESTICULAR TUMOR PROLIFERATION Toshiki Etani*, Taku Naiki, Satoshi Nozaki, Takashi Nagai, Keitaro Iida, Ryosuke Ando, Noriyasu Kawai, Satoru Takahashi, Nagoya, Japan; Takayoshi Suzuki, Kyoto, Japan; Takahiro Yasui, Nagoya, Japan INTRODUCTION AND OBJECTIVES: Lysine-specific demethylase 1 (LSD1), the first histone demethylase to be discovered, is a novel tesuticular tumor therapy target. NCL1 and NCD38, novel selective cell-active inhibitors of LSD1, were discovered at our university. We analyzed the efficacy of LSD1 inhibitors in tesuticular tumor in vitro and in vivo.
METHODS: Various tests were used to confirm the pathways responsible for germ cell tumor growth, and to characterize the anticancer effects of NCL1 and NCD38. Cell viability was assessed using a WST-8 assay with standard vehicle or NCL1 and NCD38 in NTERA2 and Tera-1 cells (human testicular embryonal carcinoma cell lines). Flow cytometry and western blotting were performed to assess the status of apoptosis and cell cycle in NCL1-and NCD38-treated NTERA2 cells. Mice injected with subcutaneous NTERA2 cell-derived tumors were injected intraperitoneally with vehicle or NCL1 and NCD38 twice a week, and tumor growth was monitored. Finally, tissue arrays were prepared from formalin-fixed, paraffin-embedded tissue specimens of 35 seminoma patients who underwent orchiectomy.
RESULTS: The WST assay revealed a reduction in the number of viable cells after NCL1 and NCD38 treatment in a dose-dependent manner in both cell lines. Western blotting confirmed that NCL1 and NCD38 treatment induced caspase-dependent apoptosis, and that Oct4 and SOX2 expression decreased. Flow cytometry confirmed that NCL1 and NCD38 significantly induced apoptosis in a dosedependent manner. Subcutaneous tumor volume was significantly lower in mice treated with NCL1 and NCD38 than in controls. TUNEL analysis showed that NCL1 and NCD38 treatment induced apoptosis in NTERA2 subcutaneous tumors. No adverse effect was observed with regard to body weight, blood toxicity, or the gross morphology of several organs in mice. Tissue array analysis showed that LSD1 expression in human seminoma specimens was significantly higher than that in noncancerous specimens.
CONCLUSIONS: Germ cell tumor growth was effectively suppressed with NCL1 and NCD38 both in vitro and in vivo in the absence of adverse events. The drugs act via induction of apoptosis and the suppression of SOX2 and OCT4, indicating the potential of these inhibitors as therapeutic agents for germ cell tumor.
